Literature DB >> 22308523

Reorienting our view of particle-based adjuvants for subunit vaccines.

Steven R Little1.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22308523      PMCID： PMC3268319          DOI： 10.1073/pnas.1120993109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  14 in total

Review 1.  Regulation of CD4 T-cell receptor diversity by vaccine adjuvants.

Authors:  Christina K Baumgartner; Laurent P Malherbe
Journal:  Immunology       Date:  2010-03-17       Impact factor: 7.397

2.  High epitope density in a single protein molecule significantly enhances antigenicity as well as immunogenicity: a novel strategy for modern vaccine development and a preliminary investigation about B cell discrimination of monomeric proteins.

Authors:  Wanli Liu; Ying-Hua Chen
Journal:  Eur J Immunol       Date:  2005-02       Impact factor: 5.532

3.  Toll-like receptor (TLR) polymorphisms in African children: Common TLR-4 variants predispose to severe malaria.

Authors:  Frank P Mockenhaupt; Jakob P Cramer; Lutz Hamann; Miriam S Stegemann; Jana Eckert; Na-Ri Oh; Rowland N Otchwemah; Ekkehart Dietz; Stephan Ehrhardt; Nicolas W J Schröder; Ulrich Bienzle; Ralf R Schumann
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-21       Impact factor: 11.205

4.  Role of target geometry in phagocytosis.

Authors:  Julie A Champion; Samir Mitragotri
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-20       Impact factor: 11.205

Review 5.  TLR-mediated cell signaling by malaria GPIs.

Authors:  D Channe Gowda
Journal:  Trends Parasitol       Date:  2007-11-05

Review 6.  New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance.

Authors:  Ric N Price; Nicholas M Douglas; Nicholas M Anstey
Journal:  Curr Opin Infect Dis       Date:  2009-10       Impact factor: 4.915

Review 7.  Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.

Authors:  Jay T Evans; Christopher W Cluff; David A Johnson; Michael J Lacy; David H Persing; Jory R Baldridge
Journal:  Expert Rev Vaccines       Date:  2003-04       Impact factor: 5.217

8.  Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax.

Authors:  Brian A Bell; James F Wood; Reeta Bansal; Hatem Ragab; John Cargo; Michael A Washington; Chloe L Wood; Lisa A Ware; Christian F Ockenhouse; Anjali Yadava
Journal:  Vaccine       Date:  2009-01-10       Impact factor: 3.641

9.  Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines.

Authors:  Steven R Little; David M Lynn; Qing Ge; Daniel G Anderson; Sidharth V Puram; Jianzhu Chen; Herman N Eisen; Robert Langer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-21       Impact factor: 11.205

10.  Towards an understanding of the adjuvant action of aluminium.

Authors:  Philippa Marrack; Amy S McKee; Michael W Munks
Journal:  Nat Rev Immunol       Date:  2009-04       Impact factor: 53.106
View more
  9 in total

1.  Working together: interactions between vaccine antigens and adjuvants.

Authors:  Christopher B Fox; Ryan M Kramer; Lucien Barnes V; Quinton M Dowling; Thomas S Vedvick
Journal:  Ther Adv Vaccines       Date:  2013-05

Review 2.  Nanoparticle approaches against bacterial infections.

Authors:  Weiwei Gao; Soracha Thamphiwatana; Pavimol Angsantikul; Liangfang Zhang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2014-07-15

Review 3.  Vaccine design: emerging concepts and renewed optimism.

Authors:  Sebastian K Grimm; Margaret E Ackerman
Journal:  Curr Opin Biotechnol       Date:  2013-03-07       Impact factor: 9.740

Review 4.  Toxoid Vaccination against Bacterial Infection Using Cell Membrane-Coated Nanoparticles.

Authors:  Pavimol Angsantikul; Ronnie H Fang; Liangfang Zhang
Journal:  Bioconjug Chem       Date:  2017-12-27       Impact factor: 4.774

Review 5.  Porous silicon advances in drug delivery and immunotherapy.

Authors:  David J Savage; Xuewu Liu; Steven A Curley; Mauro Ferrari; Rita E Serda
Journal:  Curr Opin Pharmacol       Date:  2013-07-08       Impact factor: 5.547

Review 6.  Nanocarrier-based immunotherapy in cancer management and research.

Authors:  Manu Smriti Singh; Sangeeta Bhaskar
Journal:  Immunotargets Ther       Date:  2014-06-26

Review 7.  Particle platforms for cancer immunotherapy.

Authors:  Rita Elena Serda
Journal:  Int J Nanomedicine       Date:  2013-04-29

Review 8.  Cell Membrane-Coated Nanoparticles As an Emerging Antibacterial Vaccine Platform.

Authors:  Pavimol Angsantikul; Soracha Thamphiwatana; Weiwei Gao; Liangfang Zhang
Journal:  Vaccines (Basel)       Date:  2015-10-06

Review 9.  Nanoparticle Vaccines Adopting Virus-like Features for Enhanced Immune Potentiation.

Authors:  Saborni Chattopadhyay; Jui-Yi Chen; Hui-Wen Chen; Che-Ming Jack Hu
Journal:  Nanotheranostics       Date:  2017-06-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.